392results about How to "Prevent rejection" patented technology

The present invention relates to the identification of macaque antibodies to human B7.1 and B7.2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7.1 and / or B7.2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three primatized antibodies derived from those monkey monoclonal antibodies which bind B7.1 and possibly B7.2, primatized 7C10, primatized 7B6 and primatized 16C10. These primatized and monkey antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

An implant and sleeve combination for at least partial insertion into a bone and / or cartilage. The implant includes a lower portion and the sleeve includes a cavity designed to at least partially receive the lower portion of the implant.

The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.

Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.

Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and / or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration.

The invention discloses a serial arc-fault circuit interrupter, comprising a power circuit, a current sensor, a current sensing circuit, an amplifying and filtering circuit, a voltage zero-crossing comparison circuit, a microcontroller, a trip trigger circuit. A current transformer collects current signals in a circuit; the current signals are converted into voltage signals through the current sensing circuit, and are input into the microcontroller through the amplifying and filtering circuit; the voltage zero-crossing comparison circuit inputs a voltage zero-crossing pulse signal into the microcontroller; the microcontroller judges arc emergence through arc characteristics analysis and is disconnected with a load circuit by the trip trigger circuit. The protection method transforms a one-dimensional time signal into a two-dimensional time signal by utilizing short-time Fourier transform, analyzes changes of fundamental component, even-order harmonic and odd harmonic component of eachcyclic wave, extracts and judges the serial arc-fault characteristics. The method has the advantages that multiple characteristics are extracted to realize comprehensive judgment of fault arc, missedtrip and balk generated in serial arc detection in small load are prevented, and the reliability of judgment is improved effectively.

The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.

A method of inspecting a transparent container for refractive defects includes positioning a light source in spaced relationship with respect to a detector which is operatively associated with a processor for receiving electrical signals from the detectors responsive to light passing through the container being received by the detector. The method includes positioning a grid filter having a plurality of alternating dark and light bands adjacent the light source so as to provide a multiple intensity gradient to the container. The container is positioned between the light source and the detector with the grid filter serving to provide adjacent alternate light and dark bands of light impinging on the container. Refractive defects will cause a distortion of the intensity gradient which will be received by the detector. In a preferred embodiment, a plurality of light and dark bands are generally horizontally oriented and produces a generally triangular wave having a constant absolute slope. A processor is employed to receive the electrical signals emitted by the detector responsive to the light impinging thereon and make a determination as to whether refractive defects exist while ignoring desired irregularities in the container. Corresponding apparatus which employs alternating light and dark bands in the grid filter and in the preferred embodiment employs dark bands of single intensity gradient and light bands of single intensity gradient. Each band has a constant gradient of light intensity passing therethrough. The grid filters produces a triangular wave having a constant absolute slope.

Methods for amplifying expression of interfering RNA (RNAi), and preferably siRNA or shRNA, using a RNAi (si / shRNA)-expressing concatamer, are disclosed. The methods are useful for modulating, including down-regulating and / or inhibiting, expression of a target gene in cells, including mammalian cells.

Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is achieved by having at least one optimized CDR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD20 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD20 antibodies.

Methods for sustained delivery of biologically active proteins or peptides to mammals are disclosed. Specific types of immune-privileged allogeneic or xenogenic donor cells that are naturally immune privileged are genetically modified in vitro to express or secrete the proteins or peptides. The genetically modified donor cells are subsequently implanted into host mammals and utilized for sustained delivery of biologically active proteins or peptides in vivo. The donor cells so utilized are those that inherently possess immune privilege due at least partly to the expression of Fas ligand. Methods for cell isolation, purification, tissue culture expansion, cryopreservation, gene transfer, transgene and Fas ligand expression, cell implantation, and measurement of immune responses of host animals are described.

The invention discloses a photovoltaic system fault arc detection method combining multiple detection signals. The method comprises the following steps: carrying out an equal time interval analysis of the multiple detection signals when the signal statuses are not changed; acquiring multiple characteristic values of a current time period based on a characteristic quantity obtained through the photovoltaic system fault arc detection method and the input multiple analysis time period detection signals; acquiring a typical value based on the selected detection signals; constructing correction factors for characteristic values of the next time period based on the typical values and the characteristic values of the detection signals for the current time period and the next time period; and carrying out linear weighting of each constructed correction factor and the corresponding characteristic value of the next time period to obtain a combined characteristic quantity, so as to complete the combined detection of photovoltaic system fault arcs. The method provided by the invention has the advantages that the photovoltaic system fault arc detection working conditions are expanded, the resistance of the photovoltaic system fault arc detection characteristic quantity against external interference is improved, the judgment of the combined characteristic quantity on the time of fault occurrence is more accurate, and a photovoltaic system can run more stably and safely.

A three-busbar two-section switch standby self-casting apparatus, belonging to power distribution field, includes two power supply lead-in circuit breakers, three busbar segments and two section breakers. Two standby self-casting devices being mounted on the position of the two section breakers; the standby self-casting device being equipped with a current detection loop, a voltage detection loop and a control circuit; the current detection loop using the signal of a two-path lead-in current transformer as ''non stream'' criterion, and using the current signal of the corresponding section breaker as ''over current'' criterion; while the voltage detection loop using the voltage signals of the two busbar segments, neighboring the corresponding section breaker, as ''pressure / non-pressure'' criterion. The standby power supply self-casting device includes a electrification discrimination circuit, a first and a second startup condition judgment circuit, a standby self-casting motion circuit and a rear acceleration motion circuit. The invention also discloses standby self-casting method for the apparatus. The apparatus implements power supply rapid automatic switching when the lead-in is failure under different running modes of the three-section busbar, and ensures the power supply reliability under accidents status.

The invention provides one intelligent remote close method and device to avoid electrical error operation, which comprises PAD computer, blue teeth opener and intelligent lock ware, wherein, the PAD computer is imbedded with relative operation software and blue teeth module for communication by blue teeth opener to collect relative information; it judges and sends operation order according to the rules to drive blue teeth opener; the intelligent lock ware has automatic opening and feedback information for display and relative operations by persons.

An internetworking device that provides improved immunity to Denial of Service attacks, and in general, improved Quality of Service (QoS). An internetworking element or other route processor is composed of two main parts, including a data forwarding plane and a control plane; the control plane runs routing, signaling and control protocols that are responsible for determining the packet forwarding behavior by the data plane. Independent control plane processes may be provided; however, they are considered to be a single network entity that is a uniquely addressable port. Packets thus intended for the control plane always pass through a designated point. As a result, a set of port services unique to the control plane may be applied to the control plane port. These control plane port services thus can be utilized to control all packet traffic entering and exiting the control plane processes as a whole.

The present invention relates to the identification of molecules, which are specific to CD80 and CD86 antigens. Also preferably, such antibodies are capable of inhibiting the binding of CD28 and CTLA4 to those receptors. Those molecules are able to inhibit T cell mediated immune reactions.

The current invention involves a universal fishing bait fundamentally comprised of a matrix of fibrous collagen made up into any shape or design capable of attracting fish, that is 100% biodegradable and innocuous, that has physico-chemical properties that confer it with the capacity to accommodate liberate and diffuse attractant substances, and whose physico-mechanical properties confer it a soft and flexible texture, as well as making it resistant to breakage. Likewise, the invention outlines a procedure to prepare such a bait, and a precursor paste employed in the preparation, as well as the use of fibrous collagen in the preparation of said universal fishing bait.

An immunological tolerance-inducing agent comprising a mucosa-binding molecule linked to a specific tolerogen is disclosed. Further, a method of inducing immunological tolerance in an individual against a specific antigen, including hapten, which causes an unwanted immune response in said individual comprising administration by a mucosal route of an immunologically effective amount of an immunological tolerance-inducing agent of the invention to said individual, is described.

The invention at hand describes a method for the cyclization of peptides and proteins in which linear thioesters serve as substrates. The cyclization is catalyzed by thioesterase domains of NRPS or PKS cyclases. The substrates according to the present invention are composed of one linear peptide on which a charge-stabilized aromatic, heteroaromatic or araliphatic leaving group is bound. These substrates lead to higher yields and reaction rates than linear peptides able to be cyclized with methods known so far and, furthermore, allow the cyclization of such peptides which were previously not able to be cyclized.

The invention relates to compounds of formula 1, the production and use thereof as a medicament for the treatment of diseases, particularly tumours and / or diseases caused, mediated or propagated by angiogenesis. The compounds of formula 1 are effective inhibitors of tyrosin kinases, particularly TIE-2 and VEGFR, and Raf-kinases. (I)

Methods for ex vivo administration of drugs to grafts using polymeric micro- and nanoparticles and applications for these methods are described herein. The particles contain encapsulated molecules which are released locally at the site of implantation and function to prevent graft rejection or aid in the proper adaptation of the graft to the host. The disclosed methods may be used to inhibit or reduce hyperplasia and stenosis of vascular grafts or to prevent graft rejection.

The invention relates to an adaptive cascade direction interlocking relaying method based on GOOSE (Generic Object Oriented Substation Event), which comprises the following steps: 1) initial interlocking directions of protective relays are set according to an initial interlocking direction tuning rule; 2) a directional element judges the direction of a current fault current which is compared with the initial interlocking directions by a direction comparator to judge whether the directions of two parts are the same, if yes, the step 3) is carried out, if not, IN2 is gated, and a interlocking signal is output to OUT2; 3) the direction comparator gates IN1, and outputs the interlocking signal to the OUT1 and the direction of the output signal is opposite from the initial interlocking direction at this time; 4) a receiving virtual terminal judges whether the interlocking signal is received, if yes, the interlocking is carried, if not, the step 5) is carried out; and 5) an over-current element judges whether the current fault current exceeds a local over-current protection starting fixed value, if yes, a trip signal is sent. In comparison with the prior art, the method has the advantages that the safe and reliable operation of a system is ensured and applicability is good.

This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and / or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition. Cellular-based preparations and processes for achieving cellular therapy are also provided.

The invention provides an exciting current emulation calculating method at the time of direct-current magnetic biasing. The calculating method comprises the steps of: constructing an electric network model according to a target electric network; building a transformer magnetizing current curve according to the transformer no-load excitation characteristic curve; setting direct-current magnetic biasing exciting current I0, and revising the transformer magnetizing current curve; after setting other node and shunt parameters of the electric network, carrying out emulation operation; and obtaining steady-state exciting current according to the emulation data, calculating the direct-current component I'0, revising the transformer magnetizing current curve again until I'0=I0, when I'0=I0, comparing I2 and KxbI1, and carrying out inrush current locking operation when |I2| is larger than kxb * |I1|. According to the invention, emulation calculation can be rapidly carried out on the transformer exciting current at the time of set direct-current magnetic biasing, the harmonic wave characteristics of the transformer exciting current can be effectively identified, and the influence of the exciting current at the time of direct-current magnetic biasing on the transformer protection is analyzed, thus the phenomenon that the protection element fails to operate or has unwanted operation is prevented and favorable influence is brought for the power transmission and transformation system.